## Clinical Context This patient has locally advanced esophageal squamous cell carcinoma (SCC) with HER2 overexpression. The presence of HER2 amplification in esophageal SCC is a significant prognostic and therapeutic marker. ## Management Algorithm for Locally Advanced Esophageal SCC ```mermaid flowchart TD A[Locally advanced esophageal SCC] --> B{Metastatic disease?} B -->|Yes| C[Palliative chemotherapy ± RT] B -->|No| D[Resectable disease] D --> E[Neoadjuvant chemoradiation] E --> F[Reassess for resection] F --> G[Esophagectomy] G --> H{HER2 amplified?} H -->|Yes| I[Consider adjuvant trastuzumab] H -->|No| J[Standard follow-up] ``` ## Why Neoadjuvant Chemotherapy is Correct **Key Point:** For locally advanced esophageal SCC without distant metastases, neoadjuvant chemotherapy (with or without radiation) followed by surgery is the standard of care per CROSS trial principles and NCCN guidelines. **High-Yield:** The CROSS trial (2012) demonstrated that neoadjuvant chemoradiation followed by esophagectomy improves overall survival in locally advanced esophageal cancer compared to surgery alone. Cisplatin + 5-FU is a standard neoadjuvant regimen. **Clinical Pearl:** HER2 amplification in esophageal SCC (present in ~10-15% of cases) is associated with worse prognosis and may warrant the addition of trastuzumab to chemotherapy regimens in select cases, but the immediate next step is still neoadjuvant chemotherapy, not trastuzumab monotherapy. **Tip:** Remember the sequence: neoadjuvant therapy → reassessment → surgery → adjuvant therapy if needed. Do not skip to surgery without downstaging. ## Why FISH Testing is Not the Next Step While FISH confirmation is scientifically valid, immunohistochemistry with gene amplification on biopsy is already sufficient to guide treatment decisions in this clinical context. Further molecular confirmation would delay necessary therapy.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.